UNITY Biotechnology UBX1325 KOL Call: BEHOLD Vascular Imaging Data and ENVISION Upcoming Data Readouts
About The Event
Please join us for the UNITY Biotechnology KOL webinar featuring expert Robert B. Bhisitkul, M.D., Ph.D., (University of California San Francisco School of Medicine) who will discuss UNITY’s lead asset UBX1325, a potent Bcl-xL inhibitor, as a potential treatment solution to address the unmet medical need present in the age-related diseases of the eye. The discussion will highlight data on the impact of UBX1325 on retinal vasculature in patients with diabetic macular edema (DME).
Following Dr. Bhisitkul’s presentation, the UNITY management team will provide an update on upcoming data readouts from the ENVISION study in patients with wet AMD.
A live question and answer session will follow the formal presentation.
Robert B. Bhisitkul, M.D., Ph.D., Professor of Ophthalmology, Alex Irvine MD Endowed Chair at the University of California San Francisco School of Medicine, has over 20 years of experience as a retina surgeon and clinician scientist. Dr. Bhisitkul graduated from Stanford University then combined medical school at Stanford with his Ph.D., in Neurosciences at Yale University, followed by residency and fellowship training at Harvard Medical School/Massachusetts Eye and Ear Infirmary. His translational research interest is in pre-clinical development of novel technologies for ophthalmic diseases. In clinical research, he is an investigator in major clinical trials of novel ophthalmic therapeutics, as well as studies of long-term outcomes of drug treatments for chronic eye disease. He is Director of the UCSF Retina Fellowship program. He is an Associate Examiner for the American Board of Ophthalmology and a recipient of the American Academy of Ophthalmology Achievement Award. Additionally, Dr. Bhisitkul has served as an editorial board member of American Journal of Ophthalmology Case Reports and as associate editor of the British Journal of Ophthalmology. He acts as consultant and medical advisor for ophthalmologic pharmaceutical companies in designing early-stage trials and conducting clinical development of new ocular therapies.